Physician profile
Mary S Deshields
NPI 1952411795
$457.04
in general payments reported to CMS, 2019-2025
13 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.71 · 2021: $28.07 · 2022: $15.59 · 2023: $61.94 · 2024: $118 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315 · Education: $61.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.37 |
| Education | $61.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $84.20 | 2021-2025 | Tecentriq |
| Incyte Corporation | $61.94 | 2023 | Jakafi |
| Pfizer INC. | $61.30 | 2025 | |
| Janssen Biotech, INC. | $52.59 | 2024-2025 | Erleada, Rybrevant, Akeega |
| Mindray Ds USA, INC. | $50.93 | 2024 | A7 Anesthesia System |
| Glaxosmithkline, LLC. | $30.52 | 2024-2025 | Zejula, Jemperli |
| Clovis Oncology, INC. | $23.31 | 2019 | |
| Astellas Pharma US INC | $21.06 | 2024 | Xtandi |
| Sobi, INC | $16.44 | 2024 | |
| Celgene Corporation | $15.10 | 2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $14.33 | 2025 | Welireg, Keytruda |
| Novartis Pharmaceuticals Corporation | $13.40 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Deshields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.